NCT01782963 · REGISTRY CONDITION SEARCH

Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2018-10-31

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational combination of drugs. The purpose is to learn whether the combination of drugs works in treating a specific cancer. "Investigational" means that the combination of drugs is still being studied. It also means that research doctors are trying to find out more about it. Examples of what they want to learn about are the safest dose to use, the side effects it may cause, and if the combination of drugs works for treating different types of cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Objective Response Rate

→

outcome · POSTED

Number of Participants With Grade 3 or Higher Treatment Related Adverse Events

→

outcome · POSTED

Median Progression Free Survival

→

outcome · POSTED

Median Overall Survival

→

outcome · POSTED

Median Time to Response

→

outcome · POSTED

Response Rate With Respect to Cytogenetic Characteristics

→

outcome · POSTED

Mean Plasma Bortezomib Concentration Following Intravenous and and Subcutaneous Injection

→

outcome · POSTED

Pharmacogenomic Markers of Neuropathy

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Documented symptomatic myeloma, with organ damage related to myeloma * Myeloma that is measurable either by serum or urine evaluation of the monoclonal component or by assay of serum free light chains * Must commit to complete abstinence from heterosexual contact or begin two acceptable method of birth control, one highly effective method and one additional effective (barrier) method Exclusion Criteria: * Eligible for autologous stem cell transplantation * HIV positive on combination antiretroviral therapy * Pregnant or breastfeeding * Treated with any prior systemic therapy * Primary amyloidosis or myeloma complicated by amyloidosis * Receiving other investigational agents within 14 days of the start of this trial or during this trial * Known brain metastases * Poor tolerability or known allergy to any of the study drugs or similar compounds * Intercurrent illness * Previous history of another malignant condition except for basal cell carcinoma or stage I cervical cancer * Inability to comply with an anti-thrombotic treatment regimen * Peripheral neuropathy greater than or equal to grade 2
healthy Volunteers: false
minimum Age: 60 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age) Consolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15
intervention Names
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone
label
Treatment Arm
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment Arm
name
Lenalidomide
other Names
Revlimid
type
DRUG
arm Group Labels
Treatment Arm
name
Bortezomib
other Names
Velcade
type
DRUG
arm Group Labels
Treatment Arm
name
Dexamethasone
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 50
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Participants are considered to have achieved an objective response if they meet the International Myeloma Working Group uniform response criteria for any of the following: * Stringent CR: Same as CR plus normal free light chain ratio and absence of clonal cells plasma cells in bone marrow (BM) * CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BM * VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours * PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \<200 mg per 24 hours. If the serum and urinary M-protein are not measurable, additional criteria are used to assess PR that will not fit in the space provided here. If present at baseline, a ≥50% reduction in the size of plasmacytomas is also required
measure
Objective Response Rate
time Frame
2 years

secondary Outcomes

description
A summary of the number of participants with grade 3 or higher treatment related adverse events for adverse events that had an overall incidence of greater than 15% (any grade) as assessed by Common Terminology Criteria for Adverse Events (CTCAE 4).
measure
Number of Participants With Grade 3 or Higher Treatment Related Adverse Events
time Frame
2 years
description
The median amount of time as measured from the start of treatment until either death or progression. Progressive disease requires 1 or more of the following: * \>=25% increase from lowest response level in serum M-protein (\>=0.5 g/dL absolute increase) and/or urine M-component (\>=200 mg/24hr absolute increase) * \>=25% increase in the difference between involved and uninvolved FLC levels (absolute increase \>10 mg/dL). Only for use in patients without measurable serum and M-protein levels. * \>=25% increase in bone marrow plasma cell percentage (absolute percentage \>=10%) * New or increase in existing bone lesions or soft tissue plasmacytomas * Hypercalcemia (serum calcium \>11.5 mg/dL) due solely to the plasma cell proliferative disorder.
measure
Median Progression Free Survival
time Frame
From the start of treatment until death or progression or until 3 years after the last participant is enrolled
description
The median overall survival as measured from the start of treatment until the time of death due to any cause.
measure
Median Overall Survival
time Frame
From the start of treatment until death or until 5 years after the time of disease progression
description
Median amount of time from the start of treatment until first documented response as defined by the International Myeloma Working Group uniform response criteria Stringent CR: Same as CR plus normal free light chain ratio and absence of clonal cells plasma cells in bone marrow (BM) CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BM VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \<200 mg per 24 hours. If the serum and urinary M-protein are not measurable, additional criteria are used to assess PR that will not fit in the space provided here. If present at baseline, a ≥50% reduction in the size of plasmacytomas is also required
measure
Median Time to Response
time Frame
From the start of treatment until the time of first documented response, median duration of 1.1 months
description
Response rate was assessed using the International Myeloma Working Group uniform response criteria. Stringent complete response, Complete Response, Very Good Partial Response, and Partial Response are defined in outcome measure 1. * MR included participants in whom some, but not all, criteria for PR were fulfilled, providing the remaining criteria satisfied the requirements for MR. Required all of the following: * ≥25% to ≤ 49% reduction in the level of serum monoclonal protein for at least two determinations six weeks apart. * If present, a 50 to 89% reduction in 24-hour light chain excretion, which still exceeds 200 mg/24 h, for at least two determinations six weeks apart. * 25-49% reduction in the size of plasmacytomas (by clinical or radiographic examination) for at least six weeks. * No increase in size or number of lytic bone lesions (development of compression fracture does not exclude response). * Stable Disease: Not meeting the criteria for minimal response or
measure
Response Rate With Respect to Cytogenetic Characteristics
time Frame
2 years
description
The pharmacokinetic profile of intravenous and subcutaneous bortezomib administration in combination with lenalidomide and dexamethasone.
measure
Mean Plasma Bortezomib Concentration Following Intravenous and and Subcutaneous Injection
time Frame
Day 1 (5 min, 30min, 5 hours post dose), Days 8, 15, Day 22 (pre dose and 5 min, 30 min, 5 hrs post dose), cycle 2 day 1 pre dose
description
To evaluate pharmacogenomic markers among patients with treatment related polyneuropathy.
measure
Pharmacogenomic Markers of Neuropathy
time Frame
2 years

Full study description

brief Summary: This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational combination of drugs. The purpose is to learn whether the combination of drugs works in treating a specific cancer. "Investigational" means that the combination of drugs is still being studied. It also means that research doctors are trying to find out more about it. Examples of what they want to learn about are the safest dose to use, the side effects it may cause, and if the combination of drugs works for treating different types of cancer.
detailed Description: If you are willing to participate in this study you will be asked to undergo some screening procedures and tests to confirm that you are eligible. Many of these tests and procedures are likely to be part of regular cancer care. They may be done even if it turns out that you do not take part in the research study. If you have had some of these tests or procedures recently, they may or may not have to be repeated. These tests and procedures include: a medical history, physical exam, performance status, vital signs, neurological exam, bone imaging studies, chest x-ray, bone marrow aspirate, ECG, blood tests and urine tests. If these tests show that you are eligible to participate in the research study, you will begin the study treatment. If you do not meet the eligibility criteria, you will not be able to participate in the research study. For cycles 1-9 (each cycle lasts 35 days) you will receive the following: Lenalidomide-once a day on Days 1-21. You will take Lenalidomide by mouth at the same time each day. Bortezomib- once a day on Days 1, 8, 15 and 22. If you are one of the first ten patients enrolled you will get Bortezomib as an intravenous injection for the first cycle. You will get Bortezomib as an injection under the skin for all other cycles. If you are not one of the first 10 patients enrolled you will get Bortezomib as an injection under the skin for all cycles. Dexamethasone-if you are 75 years old or younger you will get Dexamethasone on Days 1, 2, 8, 9, 15, 16, 22 and 23. If you are more than 75 years old you will get Dexamethasone on Days 1, 8, 15 and 22. You will take Dexamethasone by mouth at the same time each day. For cycles 10-15 (each cycle lasts 28 days) you will receive the following: Lenalidomide-once a day on Days 1-21. You will take Lenalidomide by mouth at the same time each day. Bortezomib-Once a day on Days 1 and 15. You will get Bortezomib as an injection under the skin. You will be given a drug diary to record taking your doses of the drugs. The study staff will tell you how to complete the diary. During the study you will have to come to the clinic for visits. The tests and procedures that will be done at each visit are listed below: Day 1 of all cycles: questions about health, medications etc., physical exam, performance status, vital signs, neurological exam, questionnaires, bone imaging studies, bone marrow aspirate, blood tests, pregnancy test, education and counseling, collection of bone marrow, plasma and serum (cycle 1 only), urine test. Day 8 of cycles 1-9: questions about health, medications etc., vital signs, blood tests. Day 15 of all cycles: questions about health, medications, etc., vital signs, blood tests, pregnancy test. Day 22 of cycles 1-9: questions about health, medications, etc., vital signs, blood tests. After the final dose of the study drug you will have an End of Treatment visit. The following tests and procedures will be done at this visit: questions about health, medications etc., physical exam, performance status, vital signs, neurological exam, questionnaires, bone imaging studies, bone marrow aspirate, blood tests, pregnancy test, education and counseling, collection of bone marrow, plasma and serum, urine test. After your End of Treatment visit, we would like to follow your status every 2 months until your disease gets worse. The following tests and procedures will be done at these follow-up visits: questions about health, medications, symptoms etc., blood tests and urine test. If you are one of the first twenty patients enrolled in the study you will also be asked to provide additional blood samples to study what the body does to the study drug. We will take one sample at five time points during cycle 1 and 2. Collection of these samples may require you to come back into the clinic on additional days when you are not receiving study drugs. You will be in this research study for about 15 months. You can be in this study for a maximum of 15 cycles. If your disease gets worse before the 15th cycle you will be taken off the study.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-fed5c2187fd35e85e96d
requested nct id
NCT01782963
primary nct id
NCT01782963
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
c12e93dc636e7b9e964ceca3102c90bd31fbe2503be2ec3637f39df1d8843b62
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-fed5c2187fd35e85e96d
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01782963
occurrences
context exact
NCT01782963
end
11
exact text
NCT01782963
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/591/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
1b475149ff68b730b7db6b4a90ff8d2c5f3484ec8583f411f338e27848beee30
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice